VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing

Reuters

2025/07/17

VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing

VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus (F-4 Filing) with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC Voyager Acquisition Corp. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a "crossover" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2170940_de), on July 17, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2552108820"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552108820\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552108820?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 13:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552108820","market":"us","top_or_hot":-1,"title":"VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus (F-4 Filing) with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC <a href=\"https://laohu8.com/S/VACH\">Voyager Acquisition Corp</a>. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a \"crossover\" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2170940_de), on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-17 13:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus (F-4 Filing) with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC <a href=\"https://laohu8.com/S/VACH\">Voyager Acquisition Corp</a>. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a \"crossover\" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2170940_de), on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VACH","symbol_name":"Voyager Acquisition Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL2JYngT:1","article_id":"2552108820","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552108820","pubTimestamp":1752728479,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus  with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC Voyager Acquisition Corp. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a \"crossover\" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VACH":"Voyager Acquisition Corp"},"translate_title":"Xlife Sciences AG子公司VERAXA Biotech AG提交F-4纳斯达克上市申请，达到重要里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VACH":0.9},"content_text":"VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing\n    \n\n        VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus (F-4 Filing) with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC Voyager Acquisition Corp. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a \"crossover\" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2170940_de), on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}